EP1521845A1 - Verfahren zum nachweis einer gesteigerten tumorsuszeptibilität - Google Patents
Verfahren zum nachweis einer gesteigerten tumorsuszeptibilitätInfo
- Publication number
- EP1521845A1 EP1521845A1 EP03738038A EP03738038A EP1521845A1 EP 1521845 A1 EP1521845 A1 EP 1521845A1 EP 03738038 A EP03738038 A EP 03738038A EP 03738038 A EP03738038 A EP 03738038A EP 1521845 A1 EP1521845 A1 EP 1521845A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- polymorphism
- mdm2
- detection
- mdm2 gene
- gene
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
Definitions
- the invention relates to a method for the detection of an increased tumor susceptibility by a specific detection of a polymorphism at position 354 A ⁇ G in exon 12 of the human murine-double-minute-gene-2 (MDM2 gene).
- This polymorphism represents a hereditary marker for an increased cancer risk in humans.
- the invention furthermore relates to the use of this tumor susceptibility marker for the development of in vitro and in vivo test systems which specifically use this marker for diagnostic, prognostic and possibly also therapeutic methods integrated.
- the mdm2 gene was first identified in the spontaneously transformed mouse cell line 3T3DM on "double minute" chromosomes. It is known that the gene product MDM2 can transform mouse fibroblasts and lead to uncontrolled and tumor-causing growth.
- the human mdm2 gene is located on the chromosome section 12ql3-14 and became more important when it was shown that it is an important opponent for the p53-
- mdm-2 Represents tumor suppressor gene.
- the mutual regulation takes place via a "feed-back loop", ie the p53 protein activates the transcription of the mdm2 gene and the MDM2 protein formed can in turn bring about the breakdown of the P53 protein.
- the MDM2 protein has ubiquitin ligase activity for P53, making the latter for the proteosomal Degradation is marked. This results in a very fine regulation of the expression of the P53 protein, which is essential especially in embryogenesis.
- mdm-2 "knock-out" mice are lethal, but survive if they also do not carry a functionally active p53 gene.
- MDM2 in addition to the interaction with the p53 tumor suppressor MDM2 also influences another tumor suppressor metabolic pathway, ie that of Rb-E2F-pl6INK4A / pl9ARF.
- MDM2 can bind to the RB protein and prevent the Rb-mediated Gl cell cycle arrest or interact directly with the transcription factors E2F1 / DP and cause the cells to transition into the S phase.
- the negative regulation of both tumor suppressor pathways which are affected in approx. 80% of all tumors, as well as numerous findings that prove that the MDM2 protein has a tumor effect, favor the mdm2 gene as a target for gene therapy.
- MDM2 can interact with numerous proteins, such as P53, CBP / p300, pRB, p73, E2F1, DPI, the L5 ribosoalene ribonucleoprotein particle, pl4ARF and RNA.
- proteins such as P53, CBP / p300, pRB, p73, E2F1, DPI, the L5 ribosoalene ribonucleoprotein particle, pl4ARF and RNA.
- sarcomas i.e. malignant tumors of mesenchymal origin.
- Sarcomas show the highest with 20-30%
- MDM2 Amplification rate for the mdm2 gene among malignancies Tumors on.
- Overexpression of MDM2 in transgenic mice results in sarcoma development (regardless of p53 status) in 38% of cases.
- MDM2 overexpression in sarcoma patients correlated significantly with poorer survival of the affected patients, which could be shown in a multivariate coxregression analysis (Würl et al. 1997).
- MDM2 (Schiott et al. 1997), a polymorphism in the 5 'untranslated area (Heighway et al. 1994) and another polymorphism in exon 10 in the zinc finger area
- the object of the invention was to determine tumor-associated mutations or polymorphisms of the human mdm2 gene and to determine their correlations with disease predispositions. Based on these correlations, a method for the molecular genetic diagnosis of these disease predispositions is to be developed. The aim is to establish a model that will result in prophylactic or alliative therapy that can be both surgical and mediocatetic.
- the invention is based on the finding that the polymorphism A ⁇ G (GAA ⁇ GAG) occurring in codon 354 of exon 12 of the MDM2 gene (nucleotide 1373 of the sequence NM_002392) is not restricted to soft tissue sarcomas, but correlates with the predisposition of various types of malignant tumors and is surprisingly hereditary in nature, ie already conserved in the germline.
- the invention therefore relates to a method for detecting tumor susceptibility, which is characterized in that a nucleic acid of a subject isolated and the sequence of the human mdm2 gene is genotyped based on the base exchange A ⁇ G (GAA ⁇ GAG) at position 354 of exon 12, a highly specific and very sensitive determination of the allelic status of this polymorphic locus (distinction between homo- and heterozygosity) preferably carried out in the high-throughput process.
- Genotyping is performed by sequencing or by other methods that are suitable for the detection of point mutations. This includes PCR-based
- Genotyping methods e.g. allele specific PCR, other genotyping methods using
- Oligonucleotides [Examples are "dot blotting” or oligonucleotide ligation assays "(OLA)], method under
- the method according to the invention is suitable for determining a wide spectrum of the most varied pre-dispositions.
- the method for the detection of the homozygous or heterozygous polymorphism A ⁇ G at position 354 (exon 12) serves as a sufficient criterion for the genetic predisposition for a potential tumor susceptibility, in particular as a sufficient criterion for the genetic predisposition for a potential tumor risk of the affected subject and for his offspring.
- the method is based on the detection of the homozygous or heterozygous polymorphism as a sufficient criterion of a potential tumor susceptibility for solid epithelial tumors, such as e.g. Prostate cancer (PCa), breast cancer, cervical cancer and / or ovarian cancer.
- PCa Prostate cancer
- the method is particularly preferably suitable for the detection of tumor susceptibility of PCa.
- the molecular biology specialist is given a universal hereditary tumor marker.
- finding this polymorphism may be the diagnostic basis for preventive measures.
- Detection is based on isolated nucleic acids, whereby both DNA and RNA can be used. Isolated RNA is rewritten into mRNA and cDNA using methods known to those skilled in the art. The DNA is then sequenced. Based on this finding, new classes of therapeutic agents can be developed according to the invention using this variable (mutated) nucleotide DNA sequence, which are directed to genes which influence the pathways of the mdm2 gene and the mdm2 gene (or related genes ) attack and act via regulation of transcription and translation and to influence their efficiency, preferably by regulating expression.
- variable (mutated) nucleotide DNA sequence which are directed to genes which influence the pathways of the mdm2 gene and the mdm2 gene (or related genes ) attack and act via regulation of transcription and translation and to influence their efficiency, preferably by regulating expression.
- genes influencing the pathways of the mdm2 gene are partly known . These include, for example:
- the invention furthermore relates to in vitro and in vivo test systems. These test systems express the sequence of the human mdm2 gene mutated at position 354A ⁇ G exon 12, and can be used to investigate diseases involving the mdm2 gene and to develop and test individually specific therapeutic agents in general.
- test systems are known to the person skilled in the art and can be cell lines, xenograft and other animal models, etc.
- PCa prostate cancer
- the method can also be integrated in a highly integrative manner into a fully automated DNA extraction from nucleated blood cells and can also be fully automated, either separately or in combination with the molecular sample preparation.
- the preferred detection method is based on a DNA ELISA and subsequent indirect enzymatic detection of the hybridization result in the 96-well format.
- this preferred embodiment of a DNA ELISA is not intended to provide further method options for molecular screening of the mdm2 locus to be examined limit.
- DNA-ELISA double-stranded DNA fragments which flank the mdm2 gene locus to be examined were generated from the previously isolated genomic DNA from the patient blood samples to be examined by means of PCR technology.
- the pair of primers used for the PCR contained a primer which was biotinylated at its 5 'position.
- the generated PCR fragment is thus also biotinylated after amplification.
- the PCR fragment is subsequently transferred to the surface of a streptavidin-coated 96-well microtest plate and covalently bound to the plate surface via the biotinylation.
- the double-stranded DNA fragment bound to the plate surface is denatured after addition of an NaOH solution and the unbound DNA single strand is removed by means of a short washing step.
- the covalently bound single strand of DNA subsequently serves as the target sequence for a base-complementary hybridization reaction for genotyping the mdm2 status.
- Hybridization is then carried out in each case with two FITC-labeled oligonucleotide probes / sample amplificate which are base complementary to the two potentially possible mdm2 allele variants at the mdm2 locus to be examined.
- the hybridization reaction is indirectly detected enzymatically by means of an enzyme-conjugated anti-FITC antibody reaction with subsequent substrate conversion.
- Evidence of the existing allele status is provided by evaluating the color changes or their intensities in the respective wells that occurred after the reaction.
- the color samples can be used to make a clear decision about the presence of homozygous or heterozygous traits become.
- the method allows 48 patient DNAs to be examined simultaneously with a 96-well plate. The reproducibility and the robustness of the method were proven within the scope of the large sample sizes examined, including blind series. Using additional DNA sequencing, the results generated in the DNA ELISA were clearly verified for a number of the samples.
- test result was reevaluated for all conspicuous samples and a representative number of inconspicuous samples and 100% independently confirmed by another recognized detection system (direct PCR-DNA sequencing, ALF Express, PharmaciaBiotech).
- the DNA samples used for this purpose come exclusively from blood donors with correspondingly hard inclusion criteria for the corresponding blood donation (no evidence of a tumor disease at the donation date or before, no known family diseases, no increased natural exposure to radiation and other mutagenic / carcinogenic substances in the professional or private area).
- PCa Prostate cancer
- Hematogenous micrometastases primarily affect the skeletal system and especially the pelvis and spine, but also individual organs such as the liver and lungs.
- surgical and drug therapies aim to suppress the formation or the effect of the hormone testosterone, which significantly promotes the proliferation of the prostate and PCa cells.
- the correct determination the tumor stage ie whether it is still a locally limited or already metastatic PCa, is therefore very important for the subsequent form of therapy.
- the current examination methods used in the primary diagnosis of PCa are digital rectal examination, the determination of the tumor marker PSA (prostate-specific antigen) in the serum and when a sample is taken . Biopsy material, its histopathological assessment and, in individual cases, the diagnostic pelvic lymphadenectomy and, if necessary.
- a beginning metastasis (disseminated PCaella in the blood, low involvement of regional lymph nodes) cannot be diagnosed in the blood up to the present time or, in the case of the lymph nodes, only postoperatively by histopathological
- CT computed tomography
- tumor volume and degree are in addition to the histological differentiation
- the determination of the tumor marker PSA is a very selective and sensitive standard method for the early detection of PCa.
- the prostate-specific antigen is not a cancer-specific, but a tissue-specific marker of the prostate. - Increased PSA Serum values indicate the presence of PCa.
- PSA values are particularly difficult in the range between 2-10 ng / ml, since BPH occurs more frequently with increasing age and the PSA value increases with increasing age due to the natural prostate growth.
- the expression of PSA is regulated by the hormones testosterone and dihydrotestosterone (DHT). With hormonal treatment of patients
- PCa Due to the health-related importance of PCa (especially in the western industrialized countries), the lack of tumor-specific markers and the known tumor biological and cellular heterogeneity of the tumor, there is an intensive search in the field of clinical research on PCa. is focused on the identification of further genetic and epigenetic cofactors for the sporadic and hereditary PCa. In the USA in particular, there are well-characterized families with an increased incidence of PCA, which allow extensive human genetic studies on (familial) PCa.
- the present invention discloses a universal hereditary tumor marker with the polymorphism A ⁇ G (GAA ⁇ GAG) at position 354 of exon 12 of the mdm2 gene, in particular for PCa.
- the polymorphism has been shown to show a strong association with PCa. With the detection of this polymorphism, an increase in the information regarding a genetic predisposition for Pca and possible associated clinical pictures can be achieved.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Health & Medical Sciences (AREA)
- Analytical Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Pathology (AREA)
- Genetics & Genomics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Oncology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Hospice & Palliative Care (AREA)
- General Engineering & Computer Science (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Urology & Nephrology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
Claims
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE2002128081 DE10228081A1 (de) | 2002-06-18 | 2002-06-18 | Verfahren zum Nachweis einer gesteigerten Tumorsuszeptibilität |
DE10228081 | 2002-06-18 | ||
PCT/EP2003/006306 WO2003106707A1 (de) | 2002-06-18 | 2003-06-16 | Verfahren zum nachweis einer gesteigerten tumorsuszeptibilität |
Publications (1)
Publication Number | Publication Date |
---|---|
EP1521845A1 true EP1521845A1 (de) | 2005-04-13 |
Family
ID=29719402
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP03738038A Withdrawn EP1521845A1 (de) | 2002-06-18 | 2003-06-16 | Verfahren zum nachweis einer gesteigerten tumorsuszeptibilität |
Country Status (7)
Country | Link |
---|---|
US (1) | US20060127900A1 (de) |
EP (1) | EP1521845A1 (de) |
JP (1) | JP2005529613A (de) |
CN (1) | CN1662661A (de) |
CA (1) | CA2489764A1 (de) |
DE (1) | DE10228081A1 (de) |
WO (1) | WO2003106707A1 (de) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2009269542A1 (en) * | 2008-07-07 | 2010-01-14 | Decode Genetics Ehf | Genetic variants for breast cancer risk assessment |
-
2002
- 2002-06-18 DE DE2002128081 patent/DE10228081A1/de not_active Withdrawn
-
2003
- 2003-06-16 CN CN038140292A patent/CN1662661A/zh active Pending
- 2003-06-16 US US10/518,317 patent/US20060127900A1/en not_active Abandoned
- 2003-06-16 CA CA 2489764 patent/CA2489764A1/en not_active Abandoned
- 2003-06-16 EP EP03738038A patent/EP1521845A1/de not_active Withdrawn
- 2003-06-16 JP JP2004513519A patent/JP2005529613A/ja active Pending
- 2003-06-16 WO PCT/EP2003/006306 patent/WO2003106707A1/de not_active Application Discontinuation
Non-Patent Citations (1)
Title |
---|
See references of WO03106707A1 * |
Also Published As
Publication number | Publication date |
---|---|
JP2005529613A (ja) | 2005-10-06 |
WO2003106707A1 (de) | 2003-12-24 |
CA2489764A1 (en) | 2003-12-24 |
CN1662661A (zh) | 2005-08-31 |
DE10228081A1 (de) | 2004-01-08 |
US20060127900A1 (en) | 2006-06-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE69629363T2 (de) | Verfahren zum nachweis von kolonkrebs aus stuhlproben | |
Hameetman et al. | The role of EXT1 in nonhereditary osteochondroma: identification of homozygous deletions | |
DE102015009187B3 (de) | Verfahren zur Bestimmung einer Mutation in genomischer DNA, Verwendung des Verfahrens und Kit zur Durchführung des Verfahrens | |
Iau et al. | Germ line mutations associated with breast cancer susceptibility | |
EP0869188A2 (de) | Verfahren zum Nachweis von Mikrosatelliten-Instabilität zur Tumordiagnostik | |
DE69632252T2 (de) | Verfahren zur erkennung von klonalen populationen von transformierten zellen in einer genomisch heterogenen zellulären probe | |
Renard et al. | Non-rhabdoid pediatric SMARCB1-deficient tumors: overlap between chordomas and malignant rhabdoid tumors? | |
Huusko et al. | Genome-wide scanning for linkage in Finnish breast cancer families | |
DE10139283A1 (de) | Verfahren und Nukleinsäuren zur Analyse von Colon-Krebs | |
DE10128508A1 (de) | Verfahren und Nukleinsäuren für die Differenzierung von Prostata-Tumoren | |
EP3981885B1 (de) | Verfahren zur bestimmung des dna-methylierungsgrads | |
FitzGerald et al. | Identification of a prostate cancer susceptibility gene on chromosome 5p13q12 associated with risk of both familial and sporadic disease | |
EP1521845A1 (de) | Verfahren zum nachweis einer gesteigerten tumorsuszeptibilität | |
DE10037769A1 (de) | Diagnose von mit CD24 assoziierten Krankheiten | |
DE19909878C2 (de) | Neue Sequenzvarianten des menschlichen MSH6-Mismatch Repair Gens und ihre Verwendung | |
DE10128509A1 (de) | Verfahren und Nukleinsäuren für die Differenzierung von Prostata- und Nierenkarzinomen | |
DE102017125335B4 (de) | Amplikon-Region als epigenetischer Marker zur Identifizierung von Immunzellen, insbesondere nicht-klassischer Monozyten | |
DE69828647T2 (de) | Diagnostisches assay zur krebsanfälligkeit | |
CN104762387B (zh) | 单核苷酸多态性rs17083838在检测垂体腺瘤中的应用 | |
DE102017125013B4 (de) | MCC als epigenetischer Marker zur Identifizierung von Immunzellen, insbesondere basophiler Granulozyten | |
DE102017125019B4 (de) | PDCD1 als epigenetischer Marker zur Identifizierung von Immunzellen, insbesondere PD1+ Zellen | |
DE102020108560B4 (de) | CBX6 als epigenetischer Marker für die Identifizierung von Immunzellen, insbesondere Gedächtnis-B-Zellen | |
EP2591124B1 (de) | Nachweis von mutationen, insbesondere deletionen oder insertionen | |
DE19544333C2 (de) | Verfahren zur Beurteilung der Aktivität von Arzneistoffen | |
DE10245779A1 (de) | Verfahren und Nukleinsäuren für die verbesserte Behandlung von proliferativen Erkrankungen von Brustzellen |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20050104 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR |
|
RIN1 | Information on inventor provided before grant (corrected) |
Inventor name: KAPPLER, MATTHIAS Inventor name: WIRTH, MANFRED Inventor name: TAUBERT, HELGE Inventor name: HILLEBRAND, TIMO Inventor name: KRUEGER, KATHARINA Inventor name: BENDZKO, PETER Inventor name: MEYE, AXEL |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN |
|
18W | Application withdrawn |
Effective date: 20061103 |